CORRECTING and REPLACING -- uniQure Announces Results for Fourth Quarter and Financial Year 2015
April 04, 2016 07:45 ET
|
uniQure
AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by uniQure N.V. (NASDAQ:QURE), the tables were not included. The corrected...
uniQure Announces Results for Fourth Quarter and Financial Year 2015
April 04, 2016 05:00 ET
|
uniQure
AMSTERDAM, the Netherlands, April 4, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced audited results for the fourth quarter and year ending...
uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease
March 22, 2016 11:05 ET
|
uniQure
AMSTERDAM, the Netherlands, March 22, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced the publication of preclinical data supporting its...
uniQure Announces Dosing of First Patient in High-Dose Cohort in Phase I/II Hemophilia B Clinical Trial
March 14, 2016 06:00 ET
|
uniQure
AMSTERDAM, the Netherlands, March 14, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has treated the first patient in the second...
uniQure to Present at the 36th Cowen & Company Health Care Conference
March 02, 2016 05:00 ET
|
uniQure
AMSTERDAM, the Netherlands, March 2, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that its management will present at the 36th Cowen &...
uniQure to Present at the RBC Capital Markets 2016 Global Healthcare Conference
February 15, 2016 05:00 ET
|
uniQure
AMSTERDAM, the Netherlands, Feb. 15, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that Dan Soland, Chief Executive Officer, will present at...
uniQure Announces Preliminary Topline Results from Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
January 07, 2016 06:00 ET
|
uniQure
--Meaningful Factor IX Expression Validates Successful Transduction of the Liver Using uniQure's Proprietary AAV5 Vector--
--Four of Five Patients Have Fully Discontinued Prophylactic Recombinant...
uniQure Announces Conference Call and Webcast to Discuss Topline Results From Low-Dose Cohort in Hemophilia B Phase I/II Gene Therapy Clinical Trial
January 06, 2016 16:15 ET
|
uniQure
AMSTERDAM, the Netherlands, Jan. 6, 2016 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company will release topline results from its...
uniQure Appoints Dan Soland as Chief Executive Officer
December 18, 2015 06:30 ET
|
uniQure
AMSTERDAM, the Netherlands, Dec. 18, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced the appointment of Dan Soland as the new Chief Executive...
uniQure Added to NASDAQ Biotechnology Index
December 14, 2015 09:34 ET
|
uniQure
AMSTERDAM, the Netherlands, Dec. 14, 2015 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology...